These cardiometabolic benefits are likely the cumulated direct and indirect effects of the studied incretin-based treatment on hyperglycemia, insulin resistance, lipotoxicity, and inflammation, all of which contribute to early diastolic dysfunction. Here, GCG is linked to Hyperglycemia.